<DOC>
	<DOCNO>NCT02799680</DOCNO>
	<brief_summary>The purpose study evaluate safety efficiency allogeneic cluster differentiation 33 ( CD33 ) -directed chimeric antigen receptor modify T cell ( CART-33 ) infusion patient relapse / refractory acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Allogeneic CART-33 Relapsed/Refractory CD33+ AML</brief_title>
	<detailed_description>The relapsed and/or refractory AML patient receive infusion allogeneic CART-33 within 1 week chemotherapy . The re-induction chemotherapy regimen primarily idarubicin cytarabine , graft-versus-host disease ( GVHD ) prevention conduct pre- post- therapy .</detailed_description>
	<criteria>Age ≥ 50 year Patient relapse and/or refractory CD33 positive acute myeloid leukemia ( AML ) Estimated life expectancy ≥ 12 week ( accord investigator 's judgment ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Previous treatment investigational gene cell therapy medicine product CD33 negative leukemia Any uncontrolled active medical disorder would preclude participation outline Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>CART</keyword>
	<keyword>AML</keyword>
</DOC>